Kresmion signals archive
157 cross-asset signals fired across commodity, crypto, equity, forex, macro. See also the Kresmion brief for 2026-05-13.
commodity (20)
Wheat volume spike - 6.2× the 20-day average (130,493 vs 21,180 avg)
Cocoa volume spike - 14.6× the 20-day average (25,336 vs 1,730 avg)
Platinum volume spike - 324.2× the 20-day average (18,772 vs 57 avg)
Copper volume spike - 25.8× the 20-day average (58,029 vs 2,246 avg)
Silver volume spike - 28.3× the 20-day average (52,628 vs 1,856 avg)
Gold volume spike - 204.9× the 20-day average (111,769 vs 545 avg)
Coffee volume spike - 8.2× the 20-day average (12,561 vs 1,529 avg)
OSINT: US Cancels 4,000‑Troop Deployment to NATO Eastern Front
RBOB Gasoline bear 6.5% vs prior close ($3.70 → $3.46)
OSINT: US-China Summit to Address Iran, Taiwan, AI, Trade and Agriculture
OSINT: Russian Deposit Activity Surges Amid Economic Pressures
OSINT: Three VLCCs Load 6M Barrels of Crude at Iran's Kharg Island
Oil +4.06% - significant rally
Coffee bear 4.8% vs prior close ($294.80 → $280.70)
Heating Oil bear 4.8% vs prior close ($4.16 → $3.96)
Cotton volume spike - 2.3× the 20-day average (26,831 vs 11,858 avg)
Oil -1.30% - significant selloff
Oil +1.17% - significant rally
Oil -1.29% - significant selloff
Silver bull 3.6% vs prior close ($85.13 → $88.15)
crypto (15)
ETH ETF inflow of $250M - institutional buying
BTC ETF inflow of $109M - institutional buying
BTC ETF inflow of $109M - institutional buying
ETH ETF inflow of $250M - institutional buying
ETH ETF inflow of $250M - institutional buying
BTC ETF inflow of $109M - institutional buying
SOL DEX volume/liquidity ratio elevated (1.05x) - strong on-chain trading activity
SOL DEX volume/liquidity ratio elevated (1.19x) - strong on-chain trading activity
ETH DEX volume/liquidity ratio elevated (0.52x) - strong on-chain trading activity
SOL DEX volume/liquidity ratio elevated (1.16x) - strong on-chain trading activity
BTC RSI 72.3 - overbought (crossed above 70)
ETH DEX volume/liquidity ratio elevated (0.51x) - strong on-chain trading activity
OSINT: US Senate Banking Committee files 100+ amendments to crypto bill ahead of markup
SOL DEX volume/liquidity ratio elevated (1.80x) - strong on-chain trading activity
BTC RSI 70.3 - overbought (crossed above 70)
equity (115)
FDA approves PRAZOSIN HYDROCHLORIDE (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves DIFLUCAN (Pfizer) - new revenue stream
FDA approves TESTOSTERONE CYPIONATE (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves DIFLUCAN (Pfizer) - new revenue stream
FDA approves TESTOSTERONE CYPIONATE (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves DISOPYRAMIDE PHOSPHATE (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves PRAZOSIN HYDROCHLORIDE (Pfizer) - new revenue stream
FDA approves DISOPYRAMIDE PHOSPHATE (Pfizer) - new revenue stream
FDA approves PRAZOSIN HYDROCHLORIDE (Pfizer) - new revenue stream
FDA approves TESTOSTERONE CYPIONATE (Pfizer) - new revenue stream
FDA approves DIFLUCAN (Pfizer) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves PRED MILD (AbbVie) - new revenue stream
FDA approves PRED MILD (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves ORILISSA (AbbVie) - new revenue stream
FDA approves ORILISSA (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves SAVELLA (AbbVie) - new revenue stream
FDA approves SAVELLA (AbbVie) - new revenue stream
FDA approves SAVELLA (AbbVie) - new revenue stream
FDA approves CREON (AbbVie) - new revenue stream
FDA approves CREON (AbbVie) - new revenue stream
FDA approves CREON (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves NAMZARIC (AbbVie) - new revenue stream
FDA approves NAMZARIC (AbbVie) - new revenue stream
FDA approves NAMZARIC (AbbVie) - new revenue stream
FDA approves PRED MILD (AbbVie) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves UNASYN (Pfizer) - new revenue stream
FDA approves UNASYN (Pfizer) - new revenue stream
FDA approves UNASYN (Pfizer) - new revenue stream
FDA approves SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (Pfizer) - new revenue stream
FDA approves SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (Pfizer) - new revenue stream
FDA approves SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves ZYMAXID (AbbVie) - new revenue stream
FDA approves ALPHAGAN P (AbbVie) - new revenue stream
FDA approves ALPHAGAN P (AbbVie) - new revenue stream
FDA approves ZYMAXID (AbbVie) - new revenue stream
FDA approves ZYMAXID (AbbVie) - new revenue stream
FDA approves ALPHAGAN P (AbbVie) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
CNC job postings down -91% WoW - potential restructuring
Ameriprise Financial search volume spiked +83 pts - unusual interest
OSINT: BT's high-price broadband contract sparks consumer backlash
Amgen search volume spiked +81 pts - unusual interest
Alphabet Inc. (Class A) search volume spiked +100 pts - unusual interest
Altria search volume spiked +78 pts - unusual interest
1 congress member filed 5 trades in TDG: net buying (5B/0S)
CF Industries search volume spiked +80 pts - unusual interest
OSINT: Dassault Rafale jets for Egypt depart France, 42 of 54 delivered
CNC job postings down -91% WoW - potential restructuring
Ameriprise Financial search volume spiked +83 pts - unusual interest
Amgen search volume spiked +81 pts - unusual interest
NVDA RSI 70.1 - overbought (crossed above 70)
Alphabet Inc. (Class A) search volume spiked +100 pts - unusual interest
Altria search volume spiked +78 pts - unusual interest
Align Technology search volume spiked +71 pts - unusual interest
1 congress member filed 5 trades in TDG: net buying (5B/0S)
CF Industries search volume spiked +80 pts - unusual interest
CNC job postings down -91% WoW - potential restructuring
Amgen search volume spiked +81 pts - unusual interest
Abbott Laboratories search volume spiked +61 pts - unusual interest
Altria search volume spiked +78 pts - unusual interest
Align Technology search volume spiked +71 pts - unusual interest
1 congress member filed 5 trades in TDG: net buying (5B/0S)
AbbVie search volume spiked +60 pts - unusual interest
CF Industries search volume spiked +80 pts - unusual interest
DASH job postings down -98% WoW - potential restructuring
CNC job postings down -91% WoW - potential restructuring
Abbott Laboratories search volume spiked +61 pts - unusual interest
OSINT: US Senate Banking Committee files 100+ amendments to crypto bill ahead of markup
Beat consensus by 77.5% - EPS $1.06 vs $0.5971 estimate
Q1-2026: Missed consensus by 19.8% - EPS $0.33 vs $0.4114 estimate
Missed consensus by 17.6% - EPS $1.48 vs $1.7967 estimate
Altria search volume spiked +78 pts - unusual interest
Align Technology search volume spiked +71 pts - unusual interest
1 congress member filed 5 trades in TDG: net buying (5B/0S)
AbbVie search volume spiked +60 pts - unusual interest
CF Industries search volume spiked +80 pts - unusual interest
DASH job postings down -98% WoW - potential restructuring
forex (4)
OSINT: BT's high-price broadband contract sparks consumer backlash
OSINT: Dassault Rafale jets for Egypt depart France, 42 of 54 delivered
OSINT: US Senate Banking Committee files 100+ amendments to crypto bill ahead of markup
DXY +0.38% - dollar strength signal
macro (3)
OSINT: Dassault Rafale jets for Egypt depart France, 42 of 54 delivered
VIX at 18.1 - CAUTION territory
Financial conditions loosening - NFCI at -0.51, liquidity supportive